RESULTS OF THE PEGASUS PHASE 3 RANDOMIZED TRIAL DEMONSTRATING SUPERIORITY OF THE C3 INHIBITOR PEGCETACOPLAN COMPARED TO ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

RESULTS OF THE PEGASUS PHASE 3 RANDOMIZED TRIAL DEMONSTRATING SUPERIORITY OF THE C3 INHIBITOR PEGCETACOPLAN COMPARED TO ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

Bibliographic Details
Main Authors:	H. Weitz, P. Hillmen, J. Szer, A. Röth, B. Höchsmann, J. Panse, K. Usuki, M. Griffin, J. Kiladjian, C. Decastro, H. Nishimori, L. Tan, M. Hamdani, P. Deschatelets, C. Francois, F. Grossi, A. Risitano, R.P. Latour
Format:	Article
Language:	English
Published:	Elsevier 2020-11-01
Series:	Hematology, Transfusion and Cell Therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2531137920303072

Similar Items

The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab
by: Richard Kelly, et al.
Published: (2009-11-01)

Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria
by: Raymond S.M. Wong
Published: (2022-07-01)

P786: THROMBOSIS AND MENINGOCOCCAL INFECTION RATES IN PEGCETACOPLAN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN THE CLINICAL TRIAL AND POST-MARKETING SETTINGS
by: Richard Kelly, et al.
Published: (2023-08-01)

P781: EVALUATION OF PEGCETACOPLAN TREATMENT SUCCESS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WITH AND WITHOUT BONE MARROW FAILURE: A MOVE TOWARDS INDIVIDUALIZED PATIENT TREATMENT
by: Jeff Szer, et al.
Published: (2023-08-01)

Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: A systematic review on efficacy and safety
by: Sangam Shah, et al.
Published: (2022-07-01)

P833: CATEGORIZING HEMATOLOGICAL RESPONSE TO PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A POST HOC ANALYSIS OF THE PHASE 3 PRINCE STUDY DATA
by: A. Risitano, et al.
Published: (2022-06-01)

PB2054: EXPOSURE-RESPONSE ANALYSES OF PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
by: Haili Ping, et al.
Published: (2023-08-01)

PB2053: POPULATION PHARMACOKINETICS OF PEGCETACOPLAN IN HEALTHY SUBJECTS AND PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
by: Haili Ping, et al.
Published: (2023-08-01)

The cost–effectiveness of pegcetacoplan in complement treatment-naive adults with paroxysmal nocturnal hemoglobinuria in the USA
by: Jesse Fishman, et al.
Published: (2023-09-01)

P839: PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH PEGCETACOPLAN SHOW IMPROVEMENTS IN D-DIMER NORMALIZATION AND DECREASE IN INCIDENCE OF THROMBOSIS
by: I. Weitz, et al.
Published: (2022-06-01)

Treatment of paroxysmal nocturnal hemoglobinuria in pregnancy with eculizumab: A case report
by: Michael J. Fassett, et al.
Published: (2021-04-01)

P840: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF PEGCETACOPLAN USING PRINCE TRIAL DATA VERSUS RAVULIZUMAB AND ECULIZUMAB IN COMPLEMENT-NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
by: R. Wong, et al.
Published: (2022-06-01)

P794: EVALUATION OF PEGCETACOPLAN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS WITH APLASTIC ANEMIA IN THE PRINCE STUDY
by: Andrija Bogdanovic, et al.
Published: (2023-08-01)

P828: NORMALIZATION OF HEMATOLOGIC AND HEALTH-RELATED QUALITY OF LIFE MARKERS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH PEGCETACOPLAN AND BASELINE HEMOGLOBIN AT OR ABOVE 10 G/DL
by: J. Panse, et al.
Published: (2022-06-01)

PB2064: THE COMPLETE STUDY: A SINGLE ARM, MULTICENTER OBSERVATIONAL STUDY TO EVALUATE EFFECTIVENESS OF PEGCETACOPLAN UNDER REAL WORLD CONDITIONS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
by: Régis Peffault de Latour, et al.
Published: (2023-08-01)

Paroxysmal nocturnal hemoglobinuria – first treatment experience with eculizumab in Slovenian patients
by: Irena Preložnik Zupan
Published: (2012-12-01)

Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations
by: Al-Ani F, et al.
Published: (2016-08-01)

Effect of Eculizumab on Iron Metabolism in Transfusion-independent Patients With Paroxysmal Nocturnal Hemoglobinuria
by: Charlotte C.M. Schaap, et al.
Published: (2023-05-01)

Eculizumab in paroxysmal nocturnal hemoglobinuria with Budd-Chiari syndrome progressing despite anticoagulation
by: Brodsky Andrés, et al.
Published: (2012-09-01)

Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
by: Di Matteo S, et al.
Published: (2024-04-01)

Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria
by: Carolyn E. Schwartz, et al.
Published: (2021-09-01)

Normalisation of haemoglobin and control of breakthrough haemolysis with increased frequency pegcetacoplan dosing in treated paroxysmal nocturnal haemoglobinuria
by: Amanda K. Davis, et al.
Published: (2023-08-01)

Switching From High-Dose Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report
by: Wolfgang Füreder, et al.
Published: (2020-08-01)

ECULIZUMAB DOSE ADJUSTMENTS DURING PREGNANCIES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A SINGLE CENTER EXPERIENCE.
by: Semra Aydin, et al.
Published: (2022-10-01)

S303: EFFECT OF PEGCETACOPLAN ON QUALITY OF LIFE IN COMPLEMENT-INHIBITOR NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE PHASE 3 PRINCE STUDY
by: D. Gomez-Almaguer, et al.
Published: (2022-06-01)

P829: A PHASE III RANDOMIZED CLINICAL TRIAL COMPARING SB12 (PROPOSED ECULIZUMAB BIOSIMILAR) WITH REFERENCE ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
by: J. H. Jang, et al.
Published: (2022-06-01)

Eculizumab before and after allogeneic hematopoietic stem cell transplantation in a patient with paroxysmal nocturnal hemoglobinuria
by: Hakan Göker, et al.
Published: (2011-08-01)

Long standing eculizumab treatment without anticoagulant therapy in high-risk thrombogenic paroxysmal nocturnal hemoglobinuria
by: Hassan A. Al-Jafar, et al.
Published: (2015-09-01)

Eculizumab before and after allogeneic hematopoietic stem cell transplantation in a patient with paroxysmal nocturnal hemoglobinuria
by: Hakan Göker, et al.
Published: (2011-09-01)

Real-World Eculizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population
by: Cheng WY, et al.
Published: (2022-05-01)

Fatigue Item Response among Hemoglobin-Normalized Patients with Paroxysmal Nocturnal Hemoglobinuria: PEGASUS Trial Results at 16 and 48 Weeks
by: Carolyn E. Schwartz, et al.
Published: (2024-03-01)

P813: EFFICACY, TREATMENT ADMINISTRATION SATISFACTION AND SAFETY OF SUBCUTANEOUS RAVULIZUMAB THROUGH 1 YEAR IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO RECEIVED PRIOR INTRAVENOUS ECULIZUMAB
by: M. N. Yenerel, et al.
Published: (2022-06-01)

Disseminated Gonococcal Infection Associated with Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria: A Case Report and Literature Review
by: Saito M, et al.
Published: (2020-07-01)

Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis
by: Ruby Sharma, et al.
Published: (2015-01-01)

Analysis of Costs per Responder in US Adults with Paroxysmal Nocturnal Hemoglobinuria with a Suboptimal Response to Prior Eculizumab Treatment
by: Jesse Fishman, et al.
Published: (2023-10-01)

Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction
by: Saad Syed, et al.
Published: (2023-06-01)

Clinical characteristics of 512 eculizumab-naive paroxysmal nocturnal hemoglobinuria patients in China: a single-center observational study
by: Yali Du, et al.
Published: (2022-12-01)

P771: PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS ON RAVULIZUMAB/ECULIZUMAB SHOWED HEMOGLOBIN RESPONSE SUPERIORITY WITH ADD-ON DANICOPAN VS PLACEBO
by: Jong Wook Lee, et al.
Published: (2023-08-01)

P838: PEGCETACOPLAN RAPIDLY STABILIZES COMPLEMENT INHIBITOR NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA EXPERIENCING HEMOLYSIS WITH ACUTE HEMOGLOBIN DECREASES; PRINCE TRIAL POST HOC ANALYSIS
by: R. Wong, et al.
Published: (2022-06-01)

Treatment of paroxysmal nocturnal hemoglobinuria
by: I. A. Lisukov, et al.
Published: (2014-07-01)